Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 20/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CCR5 | P51681 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29709355 | 1.00 | CCR1 (1.00) | CCR1CHRM2CCR5 | |
| SCHEMBL30059121 | 1.00 | CCR1 (1.00) | CCR1CHRM2CCR5 | |
| SCHEMBL993794 | 0.94 | CCR1 (0.90) | CCR1CHRM2CCR5 | |
| SCHEMBL18776064 | 0.93 | CCR1 (0.87) | CCR1CHRM2CCR5 | |
| SCHEMBL9910989 | 0.91 | CCR1 (0.87) | CCR1CHRM2CCR5 | |
| SCHEMBL993584 | 0.91 | CCR1 (0.83) | CCR1CHRM2CCR5 | |
| SCHEMBL6807717 | 0.90 | CCR1 (0.82) | CCR1CHRM2CCR5 | |
| SCHEMBL6251094 | 0.90 | CCR1 (0.82) | CCR1CHRM2CCR5 | |
| SCHEMBL6248473 | 0.90 | CCR1 (0.82) | CCR1CHRM2CCR5 | |
| SCHEMBL6249065 | 0.90 | CCR1 (0.81) | CCR1CHRM2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404300-B1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | PFIZER PROD INC (US) | 2009-09-30 | — | — | EP | claimed |
| WO-2024089691-A1 | MODULATORS AND USES THEREOF | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD (IL) | 2024-05-02 | — | — | WO | disclosed |
| EP-2614848-B1 | Inhaler and capsule for an inhaler | BOEHRINGER INGELHEIM INT (DE) | 2020-07-01 | — | — | EP | disclosed |
| US-10220165-B2 | Inhalator and capsule for an inhalator | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-03-05 | — | — | US | disclosed |
| WO-2017070431-A1 | USE OF CCR1 ANTAGONISTS AS A TREATMENT FOR TUMORS OF THE CENTRAL NERVOUS SYSTEM | MERRITT JAMES (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20170112831-A1 | USE OF CCR1 ANTAGONISTS AS A TREATMENT FOR TUMORS OF THE CENTRAL NERVOUS SYSTEM | MERRITT JAMES (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170112831-A1 | USE OF CCR1 ANTAGONISTS AS A TREATMENT FOR TUMORS OF THE CENTRAL NERVOUS SYSTEM | MERRITT JAMES (US) | 2017-04-27 | — | — | US | disclosed |
| US-8940800-B2 | Pharmaceutical compositions with enhanced performance | BEND RESEARCH, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940800-B2 | Pharmaceutical compositions with enhanced performance | BEND RESEARCH, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8772298-B2 | Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| US-20110046148-A1 | Spirocyclic Heterocycles Medicaments Containing Said Compounds, Use Thereof And Method For Their Production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-24 | — | — | US | disclosed |
| US-7887840-B2 | Bioavailability of low- solubility drugs | BEND RESEARCH, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| EP-2275091-A1 | Pharmaceutical compositions comprising adsorbates of an amorphous drug | Pfizer Products Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| EP-2245026-A1 | SPIROCYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND METHOD FOR THEIR PRODUCTION | Boehringer Ingelheim International GmbH (DE) | 2010-11-03 | — | — | EP | disclosed |
| EP-1530457-B1 | PHARMACEUTICAL COMPOSITIONS OF DRUGS IN SEMI-ORDERED FORM AND POLYMERS | BEND RES INC (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2009098061-A1 | SPIROCYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND METHOD FOR THEIR PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-13 | — | — | WO | disclosed |
| US-20080262107-A1 | A solid amorphous dispersion of a low-soluble drug and hydroxypropylmethyl celllulose acetate succinate with an ester degree of substitution of 0.85 which results in concentration-enhancement, time release agents, and storage stability; rapid crystal growth inhibitors in supersaturated aqueous solutions | PFIZER PRODUCTS INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262107-A1 | A solid amorphous dispersion of a low-soluble drug and hydroxypropylmethyl celllulose acetate succinate with an ester degree of substitution of 0.85 which results in concentration-enhancement, time release agents, and storage stability; rapid crystal growth inhibitors in supersaturated aqueous solutions | PFIZER PRODUCTS INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20060003011-A1 | Pharmaceutical compositions of drugs and neutralized acidic polymers | PFIZER INC | 2006-01-05 | — | — | US | disclosed |
| WO-2004014342-A1 | PHARMACEUTICAL COMPOSITIONS OF SEMI-ORDERED DRUGS AND POLYMERS | PFIZER PRODUCTS INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046148-A1 | Spirocyclic Heterocycles Medicaments Containing Said Compounds, Use Thereof And Method For Their Production | PKD1, BPHL, CYP11B2 | CCR1 3581/4885CHRM2 2022/4885CCR5 3069/4885 |
| US-20170112831-A1 | USE OF CCR1 ANTAGONISTS AS A TREATMENT FOR TUMORS OF THE CENTRAL NERVOUS SYSTEM | CCR1, CCR3, CCR4 | CCR1 1/4885CHRM2 1661/4885CCR5 11/4885 |
| US-20080262107-A1 | A solid amorphous dispersion of a low-soluble drug and hydroxypropylmethyl celllulose acetate succinate with an ester degree of substitution of 0.85 which results in concentration-enhancement, time release agents, and storage stability; rapid crystal growth inhibitors in supersaturated aqueous solutions | HPD, HAAO, SUCLA2 | CCR1 3742/4885CHRM2 2101/4885CCR5 4603/4885 |
| US-20060003011-A1 | Pharmaceutical compositions of drugs and neutralized acidic polymers | PDE7A, CA6, PDE9A | CCR1 1188/4885CHRM2 2122/4885CCR5 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.